M. Sequeira

发表

mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis

D. Proia, R. Bates, J. Acquaviva, 2014, Molecular Cancer Research.

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

D. Proia, K. Foley, R. Blackman, 2012, Investigational New Drugs.

Small Molecule Therapeutics Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp 90 with Ganetespib

D. Proia, R. Bates, J. Acquaviva, 2014 .

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

Manuel Sequeira, D. Proia, R. Bates, 2014, Investigational New Drugs.

Cell Death and Survival mTOR Inhibition Potentiates HSP 90 Inhibitor Activity via Cessation of HSP Synthesis

D. Proia, R. Bates, J. Acquaviva, 2014 .

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors

D. Proia, J. Acquaviva, Donald L. Smith, 2018, Clinical Cancer Research.

HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

D. Proia, R. Bates, V. Khazak, 2015, Molecular Cancer Therapeutics.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

A. Shaw, R. Doebele, D. Proia, 2013, Cancer discovery.

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression

D. Proia, N. Weigel, J. Acquaviva, 2012, International journal of oncology.

Cancer Therapy : Preclinical Preclinical Activity Pro fi le and Therapeutic Ef fi cacy of the HSP 90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

G. Shapiro, D. Proia, N. Spector, 2013 .

Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib

D. Proia, R. Bates, J. Acquaviva, 2014, Molecular Cancer Therapeutics.

Resistance to HSP90 inhibition involving loss of MCL1 addiction

D. Proia, M. Sequeira, M. MacFarlane, 2015, Oncogene.

FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

D. Proia, M. Knowles, R. Bates, 2014, Molecular Cancer Research.

Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer

G. Shapiro, D. Proia, N. Spector, 2013, Clinical Cancer Research.

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer

D. Proia, R. Bates, J. Acquaviva, 2014, Targeted Oncology.

Resistance to HSP90 inhibition involving loss of MCL1 addiction

J. L. Quesne, D. Fennell, D. Proia, 2015, Oncogene.

Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy.

M. Sequeira, E. Clark, S. Wolf, 2001, Clinical immunology.

Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

D. Proia, J. Acquaviva, Suqin He, 2012, Molecular Cancer Therapeutics.

Preclinical Development Targeting KRAS-Mutant Non – Small Cell Lung Cancer with the Hsp 90 Inhibitor Ganetespib

D. Proia, J. Acquaviva, Suqin He, 2012 .

FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

D. Proia, M. Knowles, R. Bates, 2014, Molecular Cancer Research.